louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04954118: A Different Use of The Aerosol Box in COVID-19 Patients; Internal Jugular Vein Cannulation
Official title: Use of Aerosol Box for Ultrasound-guided Internal Jugular Vein Cannulation in COVID-19 Patients; Single Center Experience
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: COVID-19 Pneumonia
Keywords: Aerosol box
SARS-CoV-2 virus
COVID-19
Internal jugular vein
Personal protective equipment
Lead sponsor: Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Sponsor class: OTHER_GOV
First posted: 2021-07-08
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Parallel Assignment
Primary purpose: PREVENTION

Brief summary: During the COVID-19 pandemic, health employees are at high risk of infection. This study aimed to determine experiences with an aerosol box (AB), used with the aim of preventing contamination by droplets during internal jugular vein cannulation which requires close contact with COVID-19 patients, and the necessity to use this device.

Detailed description: The study included 40 patients with diagnosis of COVID-19 requiring central venous catheter during treatment in the ward. The patients were randomly allocated to one of the two protective equipment groups and, then, randomly assigned to one of the five clinicians. Group P\&A had both personal protective equipment (PPE) and AB used, while Group P included patients where PPE was used alone. Clinicians completed a survey after performing the procedure to evaluate the use of the aerosol box. Collected data of the procedures and patients, were analyzed. In addition, survey data were evaluated.

Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with COVID-19 and inserted central venous catheter while being treated in the ward

Exclusion Criteria:

* Patients under the age of 18 years
* Patients who can not lie in the supine position due to severe respiratory distress,
* Patients with thrombus in the right İJV in evaluation with US

Primary outcomes:
measure: Questionnaire on the Use of Aerosol Boxes
timeFrame: 7 months from the index case of the pandemic in Turkey
measure: Catheter-related infection after central venouse catheterization in COVID-19
timeFrame: 7 months from the index case of the pandemic in Turkey
Secondary outcomes:
measure: Number of arterial punctures
timeFrame: 7 months from the index case of the pandemic in Turkey
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Bakirkoy Dr. Sadi Konuk Research and Training Hospital
state: Bakirkoy
Study officials:
References:
Clinical trial NCT01149018: Efficacy Trial of Oral Tetrahydrocannabinol in Patients With Fibromyalgia
Official title: A Randomized, Double-blind, Placebo-controlled Trial of Oral Tetrahydrocannabinol (∆-9-THC) in Patients With Fibromyalgia
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Fibromyalgia
Keywords: Fibromyalgia
Tetrahydrocannabinol
Chronic Widespread Pain
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
Collaborators: name: Hebrew University of Jerusalem
First posted: 2010-06-23
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of the study is to evaluate the effectiveness of oral tetrahydrocannabinol in patients suffering from Fibromyalgia


Eligibility criteria: Inclusion Criteria:

- Adult (\>18y.o) Patient with Fibromyalgia, diagnosed by ACR criteria

Exclusion Criteria:

- Children \< 18 years old

Patients with following psychiatric disorders:

* Psychosis or history of acute psychosis
* Schizophrenia
* Bipolar disorder Patients smoking marijuana, using hashish or any other form of cannabis. Patients with history of drug abuse or illicit drug use Patients receiving chronic treatment with strong opioids (Morphine, Oxycodone, Fentanyl, Methadone, Hydromorphone, Buprenorphine, Pethidine). Weak opioids as Tramadol or Propoxyphene will be allowed.

Pregnant patients

Primary outcomes:
measure: Meaningful change in Total score on Fibromyalgia Impact Questionnaire (FIQ)
timeFrame: 8 weeks
Secondary outcomes:
measure: Meaningful change in Brief Pain Inventory average pain severity.
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Pain Relief Unit, Hadassah Medical Organisation
Study officials:
References:
Clinical trial NCT06235918: Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma
Official title: Neoadjuvant Tislelizumab (BGB-A317, Anti-PD-1 Antibody) Plus Nab-Paclitaxel and Carboplatin for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma : A Single-arm, Phase II Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Head and Neck Squamous Cell Carcinomas
Resectable Head and Neck Squamous-cell Carcinoma
Lead sponsor: Tongji Hospital
Sponsor class: OTHER
First posted: 2024-02-01
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: For resectable squamous cell carcinoma of the head and neck , novel therapeutic approaches are still needed to improve outcomes. Neoadjuvant immunochemotherapy is considered as a potentially effective strategy. The purpose of this study is to evaluate the safety and efficacy of neoadjuvant of tislelizumab combined with platinum doublet for resectable locally-advanced head and neck squamous-cell carcinoma .


Eligibility criteria: Inclusion Criteria:

1. Patients who voluntarily participate in the project and sign the informed consent.
2. Be 18 years of age on day of signing informed consent.
3. The performance status of the Eastern Cooperative Oncology Group (ECOG) is 0-1.
4. According to the 8th edition of the guidelines of the American Joint Committee on Cancer (AJCC), patients with stage III-IVA tumors confirmed by pathology as head and neck squamous cell carcinoma.
5. Resectable tumors were evaluated by head and neck surgeons before enrollment to exclude clinical evidence of distant metastasis.
6. Demonstrate adequate organ function.

Exclusion Criteria:

1. The patient has abnormal blood indicators, abnormal liver and kidney function.
2. The patient has received prior systemic anti-cancer therapy for head and neck squamous cell carcinoma including investigational agents within 3 months of first dose of study treatment.
3. The patient has previously suffered from other tumors , or has previously undergone anti-tumor treatments such as surgery, chemotherapy, and radiotherapy within the past 5 years.
4. The entire clinical research process cannot be completed due to personal, social and economic reasons.
5. Serious systemic diseases in the past and the diseases cannot be cured or controlled by drugs .

Primary outcomes:
measure: Pathological Complete Response (PCR)
timeFrame: From neoadjuvant therapy to surgical resection, up to 6 weeks
Secondary outcomes:
measure: Major Pathological Response (MPR)
timeFrame: From neoadjuvant therapy to surgical resection, up to 6 weeks
measure: 3-year Disease-free survival (DFS) rate
timeFrame: 3-years after surgery
measure: 3-year overall survival（OS）rate
timeFrame: 3-years after surgery
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Tongji Hospital
state: Hubei
Study officials:
affiliation: Tongji Hospital
name: Guangyuan Hu, professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00203918: Prostate Cancer Utilities and Cost-Effectiveness Analysis
Official title: Prostate Cancer Utilities and Cost-Effectiveness Analysis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Prostate Cancer
Keywords: Prostate Cancer
Cost-Effectiveness Analysis
Utility Assessment
Lead sponsor: University of Chicago
Sponsor class: OTHER
First posted: 2005-09-20
Enrollment: 481
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients visiting the urology clinic at the University of Chicago.

Brief summary: The purpose of this study is to help doctors and patients make better decisions about prostate cancer treatment. This research is being done because we do not know how patient preferences for health states related to prostate cancer affect the final treatment decision.

Detailed description: The goal of this project is to incorporate patients' preferences into a previously developed prostate cancer treatment decision-model and to understand the implications for doing so for cost-effectiveness analysis. To do this, it is first necessary to obtain patient utility scores (i.e., patient preference weights). To do this we will perform a survey of patients visiting the urology clinic to undergo prostate biopsies to validate a method of utility assessment, and understand the patients' individual evaluations of treatment-related health studies. We will also ask patients questions relating to their anxiety levels concerning the possible diagnosis of prostate cancer.

Eligibility criteria: Inclusion Criteria:

* Patients undergoing prostate biopsy

Exclusion Criteria:

* Women and children will be excluded, as prostate cancer occurs in men only
* Diagnosis of dementia

Primary outcomes:
measure: Utility scores for treatment outcomes
timeFrame: 90 days after enrollment
Secondary outcomes:
measure: Anxiety levels
timeFrame: 90 days after enrollment
Other outcomes:
Locations:
city: Chicago
country: United States
facility: The University of Chicago
state: Illinois
Study officials:
affiliation: University of Chicago
name: David Meltzer, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05210218: Cinnamon and Withania on Weight Loss
Official title: Effect on Weight Loss of an Oral Association of Cinnamon Bark (Cinnamomum Cassia) and Withania Somnifera in Adult Patients With Overweight or Obesity: a Randomized, Prospective, Placebo-controlled, Multicenter, Cross-over, Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Lead sponsor: University of Roma La Sapienza
Sponsor class: OTHER
First posted: 2022-01-27
Enrollment: 40
Sex: ALL
Minimum age (years): 25
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: With the prevalence of obesity soaring and the absence of an effective and safe treatment that is low-cost and always feasible, the use of food supplements has gained attention for the potential benefits in the absence of significant safety concerns. Cinnamon (CC) and Withania somnifera (WS) are plant-based supplements reported to be effective in improving metabolic health and body composition, the first mainly acting on insulin resistance and the second on energy expenditure and leptin resistance, as shown in preclinical and some clinical studies. Their association, possibly synergistic leveraging different mechanisms of action, has never been studied.

This was a double-blind placebo-controlled study. Patients with overweight or obesity were prescribed a mildly hypocaloric diet with CC 300 mg plus WS 150 mg tid for 4 weeks in a cross over design and anthropometric parameters together with safety outcomes were collected.


Eligibility criteria: Inclusion Criteria:

* age range: 25-75 years
* overweight or obesity (BMI range: 26-35)

Exclusion Criteria:

* heart failure
* congenital cardiomyopathies
* episodes of tachy/brady-arrythmias
* acute myocardial infarction within 3 months from the enrollment
* inability or unwillingness to provide informed consent
* pregnancy

Primary outcomes:
measure: weight change
timeFrame: at baseline and at every follow up visit, through study completion, an average of 10 weeks
Secondary outcomes:
measure: waist circumference change
timeFrame: at baseline and at every follow up visit through study completion, an average of 10 weeks
Other outcomes:
Locations:
city: Roma
country: Italy
facility: Sapienza University of Rome
state: RM
Study officials:
References:
Clinical trial NCT04373018: Evaluation of Three Irrigants, Sodium Hypochlorite, Chlorhexidine and Combination of CHX+H2O2 in Endodontic Treatment.
Official title: Comparative Evaluation of Clinical and Radiographic Outcome by Using Three Different Irrigants, Sodium Hypochlorite (NaOCl), Chlorhexidine (CHX) and Combination of CHX+H2O2 in Primary Endodontic Treatment
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Periapical Periodontitis
Keywords: Sodium hypochlorite
Chlorhexidine
Hydrogen peroxide
Lead sponsor: Postgraduate Institute of Dental Sciences Rohtak
Sponsor class: OTHER
First posted: 2020-05-04
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will evaluate the synergistic effect of CHX + H2O2 when used as an irrigant during biomechanical preparation.in root canal treatment on periapical healing and compared with Chlorhexidine( CHX) and Sodium Hypochlorite (NaOCl).

Detailed description: After a thorough history, clinical and radiographic examination with all eligibility confirmation, written informed consent will be taken from the patient after explaining the procedure and its associated risks and benefits. Patients randomly allocated to one of the three study groups Sodium hypochlorite (NaOCl), Chlorhexidine (CHX) and combination of (CHX+H2O2). All three irrigants will be used according to standard protocol during biomechanical preparation. Pain analysis will be carried out preoperatively and postoperatively at every 6 hours for 1 day and then every 24 hours till 7 days after the intervention. All the subjects will be followed up for evaluation of clinical and radiographic success at 3, 6 months and 1year.

Eligibility criteria: Inclusion Criteria:

* All patients over 18 years of age.
* Mature permanent mandibular molars.
* A radiographic evidence of periapical radiolucency (minimum size \> 2mm×2mm) and a diagnosis of pulpal necrosis, as confirmed by the negative response to cold and electrical tests; and absence of bleeding on entering the pulp chamber.

Exclusion Criteria

* Diabetics, immunocompromised patients, pregnant females, any systemic disease.
* Patients with a history of analgesic intake within the past 3 days and antibiotics in the last month.
* Patients with pockets ≥ 4mm or having marginal or furcal bone loss due to periodontitis.
* Non-restorable tooth, fractured, perforated roots and inflammatory root resorption.
* Teeth those are not suitable for rubber dam isolation.
* Primary teeth.

Primary outcomes:
measure: Clinical success
timeFrame: Base line to 1 year.
Secondary outcomes:
measure: Radiographic success
timeFrame: Baseline to 1 year
measure: Pain assessment
timeFrame: Baseline to 7 days
Other outcomes:
Locations:
city: Rohtak
country: India
facility: PGIDS, Rohtak
state: Haryana
Study officials:
affiliation: PGIDS, Rohtak
name: Anshu Yadav
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04224818: Dual Trigger in the Final Oocyte Maturation in Poor Ovarian Responders
Official title: Dual Trigger in the Final Oocyte Maturation in Poor Ovarian Responders: A Prospective Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Poor Ovarian Reserve
Lead sponsor: American University of Beirut Medical Center
Sponsor class: OTHER
First posted: 2020-01-13
Enrollment: 140
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 44
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a randomized controlled clinical trial to investigate the effect of dual trigger (hCG and GnRH agonist) on the final oocyte maturation compared to the standard hCG trigger in patients with poor ovarian reserve seeking IVF/ICSI treatment.

Detailed description: Women with POR (Bologna criteria) manifest a very low follicular response to controlled ovarian stimulation irrespective of the stimulation protocol utilized. Dual triggering of oocyte maturation was shown to improve follicle collection yield and oocyte maturation in women with predicted normal ovarian response. These benefits have been attributed to the GnRHa-induced FSH surge believed to promote oocyte nuclear maturation and cumulus expansion. The aim of the study is to show whether the co-administration of a GnRH agonist and hCG for final oocyte maturation improve oocyte collection and maturation rate

Eligibility criteria: Inclusion Criteria:

* Normal uterine cavity (as assessed by hysteroscopy or HSG).
* Normal hormonal investigation: TSH, PRL.
* Low ovarian reserve patients (AMH\<1.5ng/ml, AFC of 7 or less, 5 oocytes or less retrieved in a previous cycle)

Exclusion Criteria:

* Abnormal uterine cavity (Hysteroscopy or HSG)
* Evidence of untreated endocrine disorders (abnormal TSH, prolactin, testosterone and androstenedione concentrations)

Primary outcomes:
measure: Number of oocytes retrieved (oocyte collection rate)
timeFrame: 38 hrs
measure: Number of mature oocytes (oocyte maturation rate)
timeFrame: 38 hrs
Secondary outcomes:
measure: Fertilization rate
timeFrame: 48 hrs
measure: Clinical pregnancy rate
timeFrame: 7 weeks
measure: Implantation rate
timeFrame: 7 weeks
measure: Miscarriage rate
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Beirut
country: Lebanon
facility: American University of Beirut Medical Center
Study officials:
affiliation: American University of Beirut Medical Center
name: Ghina S Ghazeeri, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04046718: Lipid Profile Response to Electroacupuncture Stimulation in Non Alcoholic Fatty Liver Patients
Official title: Lipid Profile Response to Electroacupuncture
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Fatty Liver , Electroacupuncture, Lipid Profile
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2019-08-06
Enrollment: 60
Sex: FEMALE
Minimum age (years): 30
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: two group study, one is the study group and the other is a control group
Primary purpose: TREATMENT

Brief summary: sixty female patients suffering from non-alcoholic fatty liver disease were randomly divided into two equal groups group 1 received electroacupuncture stimulation for 6 weeks at special points of stimulation. group 2 was a control group that received nothing without any change in lifestyle and we assed the response of lipid profile post-treatment protocol in both groupes


Eligibility criteria: Inclusion Criteria:

non alcoholic fatty liver BMI 30-40

Exclusion Criteria:

* Patients with: (Hepatitis C \& b any form of seizure

Primary outcomes:
measure: tri-triglycerides (mg/dl) , total cholesterol (mg/dl) , HDL (mg/dl) , LDL (mg/dl)
timeFrame: 6 weeks
Secondary outcomes:
measure: weight (kg) , height (m), BMI (kg/m2)
timeFrame: 1st week
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: faculty of physical therapy Cairo university
Study officials:
References:
citation: Draz RS, Serry ZMH, Rahmy AF, El Bardesi MS, Taha MM. Electroacupuncture Versus Aerobic Interval Training on Liver Functions in Patients with Nonalcoholic Fatty Liver. J Altern Complement Med. 2020 Jan;26(1):51-57. doi: 10.1089/acm.2019.0182. Epub 2019 Oct 29.
Clinical trial NCT02813018: The Impact of Preemptive Epidural Analgesia on Acute Postoperative Pain in Pediatric Orthopedic Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pediatric Surgical Patients
Preemptive Epidural Analgesia
Keywords: child
analgesia
epidural
pain
postoperative
orthopedics
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2016-06-24
Enrollment: 50
Sex: ALL
Minimum age (years): 3
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Management of postoperative pain is critical in the pediatric patients, however, safe and effective analgesia for pediatric surgical patients remains a challenge. Preemptive analgesia is based on preventing a prolonged change in central nervous system function by blocking afferent input before the surgical stimulation may evoke central sensitization and aggravate amplification and prolongation of postoperative pain. However, the clinical efficacy of preemptive analgesia is still controversial. In this study, the investigators aim to assess the impact of preemptive epidural analgesia on postoperative pain in pediatric patients for corrective osteotomy of the lower extremities expecting severe postoperative pain.


Eligibility criteria: Inclusion Criteria:

* Pediatric patients (3-12 years of age) scheduled for corrective osteotomy of the lower extremities
* ASA class I and II

Exclusion Criteria:

* Coagulopathy
* Neurological disease
* Allergy to local anesthetics or contraindication to use of ropivacaine
* Infection at the site of epidural catheter insertion

Primary outcomes:
measure: FLACC scale score (Face, Legs, Activity, Cry, Consolability)
timeFrame: 0-6 hours after the operation
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine
Study officials:
References:
citation: Al-Shaikh B, George William M, Van Zundert AA. Using atmospheric pressure to inflate the cuff of the Portex Laryngeal Mask. Anaesthesia. 2005 Mar;60(3):296-7. doi: 10.1111/j.1365-2044.2005.04135.x. No abstract available.